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Abstract
Expansions of the polyglutamine (polyQ) domain ($34) in Ataxin-2 (ATXN2) are the primary cause of spinocerebellar ataxia
type 2 (SCA2). Recent studies reported that intermediate-length (27–33) expansions increase the risk of Amyotrophic Lateral
Sclerosis (ALS) in 1–4% of cases in diverse populations. This study investigates the Turkish population with respect to ALS
risk, genotyping 158 sporadic, 78 familial patients and 420 neurologically healthy controls. We re-assessed the effect of
ATXN2 expansions and extended the analysis for the first time to cover the ATXN2 locus with 18 Single Nucleotide
Polymorphisms (SNPs) and their haplotypes. In accordance with other studies, our results confirmed that 31–32 polyQ
repeats in the ATXN2 gene are associated with risk of developing ALS in 1.7% of the Turkish ALS cohort (p=0.0172).
Additionally, a significant association of a 136 kb haplotype block across the ATXN2 and SH2B3 genes was found in 19.4% of
a subset of our ALS cohort and in 10.1% of the controls (p=0.0057, OR: 2.23). ATXN2 and SH2B3 encode proteins that both
interact with growth receptor tyrosine kinases. Our novel observations suggest that genotyping of SNPs at this locus may
be useful for the study of ALS risk in a high percentage of individuals and that ATXN2 and SH2B3 variants may interact in
modulating the disease pathway.
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Introduction
ALS is a late-onset, rapidly progressive and devastating
neurodegenerative disorder, which is generally associated with
selective degeneration of both upper and lower motor neurons
(MNs) in the brain, brainstem and spinal cord. Ten per cent of all
ALS cases are inherited and referred to as familial ALS (fALS); the
remaining 90% are sporadic (sALS) [1]. Although the mechanisms
causing ALS are not well understood yet, several genes have been
linked to the disease. Among these, SOD1 involved in oxidative
stress, TARDBP and FUS implied in RNA-processing
[2,3,4,5,6,7], and the two recently identified UBQLN2 and
C9ORF72 genes are the most prominent causes of fALS
[8,9,10]. Recently, genome wide association studies (GWAS) have
identified SNPs that are associated with sALS, underscoring the
importance of investigating common genetic variations [11,12,13].
In addition to rare mutations and common SNPs, a recent
publication reported that ATXN2 dysfunction influences the
TDP-43-dependent toxicity seen in ALS and that the intermedi-
ate-length expansions to 27–33 triplets in the ATXN2 polygluta-
mine (polyQ) region act as ALS risk factors in 4.7% of North
American patients [14]. All follow-up studies confirmed the
association of the ATXN2 polyQ expansions with ALS risk in
various ethnic populations, including North Americans, Europe-
ans, French-Canadians and Chinese [14,15,16,17,18,19,20].
Further, North-American studies investigated the specificity of
the association between ATXN2 and ALS. Ross et al. demon-
strated that intermediate-length polyQ expansions are associated
with neither Alzheimer’s nor idiopathic Parkinson’s diseases, but
with ALS and the Parkinson-plus entity progressive supranuclear
palsy [19]. In addition, Lee et al. as well as Gispert et al. reported
that among several other polyQ neurodegenerative disease
proteins, only ATXN2 is associated with ALS risk [21,22],
suggesting that the physiological functions of ataxin-2 in RNA
processing and/or receptor tyrosine kinase endocytosis are
relevant [23,24,25,26,27]. The polyQ expansion is thought to
convey a gain-of-function (GOF) effect on the ataxin-2 protein and
to provoke insolubility and aggregation of ataxin-2 with its
interacting proteins [28,29,30]. However, a loss-of-function of
ataxin-2, in addition to its GOF, cannot be excluded, since both
mechanisms seem to be important modulators of disease
manifestation in several neurodegenerative diseases [31].
PLOS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e42956ATXN2 usually contains a repeat structure with 22 or 23 triplets
coding for glutamine and the (CAG)8CAA(CAG)4CAA(CAG)8
sequence;expansionofthisdomaintoasize$34tripletswitha pure
CAG sequence primarily causes autosomal dominant SCA2 [32],
while ATXN2 expansions withCAAinterruptions wereobserved as
the cause of Levo-dopa responsive Parkinson’s disease [33].
ATXN2 expansions associated with ALS were reported by Corrado
et al. to be interrupted by at least one CAA triplet [16], Yu et al.
identified ATXN2 expansions in 40 ALS patients to be always
interrupted by CAA triplets, and defined a haplotype of two
ATXN2 SNPs (rs695871 and rs695872) in common between most
cases with 3 CAA interruptions and another haplotype in common
between most cases with 1–3 CAA interruptions [34,35].
This study now aims to investigate the association of the
ATXN2 chromosomal region with ALS risk in the Turkish
population, considering not only the polyQ repeats, but also
common SNPs and haplotype patterns.
Materials and Methods
Ethics Statement
The Ethics Committee of Bog˘azic ¸i University approved the use
of patient samples for this study. Written informed consent forms
were obtained from all patients. Control samples were collected
anonymously.
PolyQ Expansion Analyses
A total of 236 Turkish ALS patients (158 sALS and 78 fALS)
matching El Escorial Criteria [36] were referred to our center
from several hospitals throughout Turkey. Fifteen of these patients
had already a defined mutation in one of the genes responsible for
ALS and these were also included in the study, in addition to 420
Turkish healthy controls without any known history of neurolog-
ical disorders. These control samples were collected from the
Microbiology Department of Haydarpas ¸a State Hospital in
Istanbul. The mean ages of onset of sALS and fALS patients
were 48.9 (range: 24–79) and 34.3 (range: 8–80) years, respec-
tively. The average age of the control group was 63.8 (range: 38–
97). Male to female ratios were 3:2 for sALS, 1:1 for fALS and 1:1
for controls. DNA was extracted from peripheral blood cells of
patients and controls, using the MagNAPure Compact (Roche)
DNA isolation systems.
The ATXN2 triplet repeat was amplified from DNA samples of
patients and healthy controls, using polymerase chain reaction
(PCR) with the forward primer 59- GGG CCC CTC ACC ATG
TCG -39 and the FAM labeled reverse primer 592/56-FAM/
Figure 1. Distribution of ATXN2 repeat sizes, represented as polyQ triplet numbers. Turkish ALS patients are represented in red and
healthy controls in blue bars; numbers of the individuals having the relevant alleles are shown on the top of each bar.
doi:10.1371/journal.pone.0042956.g001
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5 min. at 95uC, 30 cycles (1 min. at 95uC, 1 min. at 55.7uC,
1 min. and 30 sec. at 72uC) and 5 min. at 72uC. Repeat sizes were
determined by GeneScan Analysis (Macrogen Inc., Seoul, Korea)
and evaluated independently by two authors (SL and O ¨ O ¨ ). The
reproducibility of the GeneScan analyses was validated via
repeating 25 samples among 236 ALS cases and 45 samples out
of 420 controls, corresponding to ,10% of both cohorts. A SCA2
positive individual with 41 ATXN2 repeat expansion size was used
as an internal control in both PCR amplifications and GeneScan
analyses. ALS patients with an ATXN2 expansion were further
subjected to DNA sequencing, to assess the presence of CAA
interruptions (RefGen Inc, Ankara, Turkey).
Fisher’s exact test was applied to evaluate the genetic association
of ATXN2 expansion sizes with ALS risk, under both the allelic
and genotypic models.
SNP and Haplotype Association Analyses
In our independent GWA study (unpublished data) performed
earlier, we investigated 733,202 SNPs in 116 out of the above 158
Turkish sALS patients and 109 age- and sex- matched neurolog-
ically healthy individuals, using the Illumina HumanOmniExpress
SNP array. To examine the association of ATXN2 locus variants
with ALS risk in the Turkish cohort under study, we extracted
250 kb genotype data, comprising the ATXN2 locus and the
surrounding 50 kb (25 kb from 59 and 39 ends) using PLINK
software (http://pngu.mgh.harvard.edu/purcell/plink/) [37]. The
SNPs with a Hardy-Weinberg equilibrium (HWE) of .0.05 and a
minor allele frequency (MAF) of .0.01 were included. Haploview
4.2 software was also used to visualize the haplotype blocks in the
ATXN2 and the neighbouring SH2B3 genes (http://www.broad.
mit.edu/haploview/haploview) [38]. The haplotype blocks, in-
cluding SNPs in linkage disequilibrium (LD), were determined via
the Gabriel method (CI: 0.98–0.7) [39]. We performed 1000
permutation tests to generate empirical p-values.
Results
ATXN2 Expansion Analyses
We investigated the ATXN2 expansion sizes of 236 ALS
patients and 420 healthy controls from Turkey, using GeneScan
analysis. The lengths of the ATXN2 repeat alleles varied from 13
to 32 units in ALS patients and from 15 to 29 units in controls
(Figure 1). The commonly found 22 repeat allele accounted for
approximately 92% of both ALS and control populations. None of
the 15 ALS patients, carrying various mutations in different ALS
disease genes (SOD1, FUS, UBQLN2, OPTN, SPG11 and
PLEKHG5) showed expansions in ATXN2 (p=0.78) (Table S1).
In the allelic model, the MAF of the 31 allele was 0.21% (1/472
alleles) in cases, whereas this allele was absent in controls. The
MAF of the 32 allele was 0.63% (3/472 alleles) in cases and again
this allele was absent in controls. Fisher’s exact test detected a
significant difference for alleles coding a polyQ size .30 between
cases and controls (p=0.016). Also in the genotypic model, the
heterozygous presence of a polyQ size .30 showed statistically
significant association with ALS risk according to Fisher’s exact
test (p=0.0172) (Table 1). Sequencing of the ATXN2 expansions
of the four ALS patients with sizes 31 and 32 showed that three
patients had a single CAA interruption within the CAG repeat,
while the remaining patient has a pure CAG tract. Clinical
information and the sequence data of these four ALS patients are
shown in Table 2.
ATXN2 Locus SNP and Haplotype Association Analyses
We investigated a 250 kb region on chromosome 12q in 116 out
of the above 158 Turkish sALS patients, including two of the four
ALS patients with ATXN2 expansions. Ten of 28 SNPs were
excluded due to low HWE and MAF scores. In single marker
analysis, none of the SNPs within the ATXN2 gene by itself
showed any significant association with ALS risk, but a trend
towards association was observed for the SNP rs2239194 within
the SH2B3 gene (p=0.063) (Table S2). On the other hand,
haplotype analysis of the region, using the Haploview program,
demonstrated a strong association for a 136 kb 15-SNP haplotype
block (including rs2239194), which contains both the ATXN2 and
SH2B3 loci. One haplotype (GGGGAAGAGAAGGAC,
MAF=0.149, Fcases=0.194, Fcontrols=0.101) had a significant p-
value of 0.0057 and correlated with an increased ALS risk (OR:
2.23). This risk haplotype was observed in heterozygous state in
both Turkish ALS patients with ATXN2 expansions, which were
part of the GWA genotyping study. Using permutation analysis,
which eliminates false positive data after multiple testing more
effectively than Bonferroni corrections [40], this haplotype-risk
association retained its statistical significance (p=0.02) after 1000
permutations (Figure 2).
Table 1. The frequency of ATXN2 expansion sizes in ALS and
controls (in the genotypic model).
#30 repeats .30 repeats p-value
a
ALS (n=236) 232 (98.3%) 4 (1.69%) 0.01721
Controls (n=420) 420 (100%) 0
aFisher’s exact test.
doi:10.1371/journal.pone.0042956.t001
Table 2. Clinical characteristics of four Turkish ALS patients with ATXN2 expansions.
ALS No Gender Birth AO AD Site of Onset Genotype Sequence Composition
sALS20* female 1950 52 57 LE 22/31 (CAG)21CAA(CAG)9
sALS39 male 1962 39 44 LE 22/32 (CAG)32
sALS180* female 1929 77 alive Bulbar 22/32 (CAG)22CAA(CAG)8
fALS304 female 1982 8 alive Bulbar, LE 23/32 (CAG)23CAA(CAG)8
AO: age of onset, AD: age at death. UE: upper extremity, LE: lower extremity, ULE: upper and lower extremity.
*GWA- genotyped.
doi:10.1371/journal.pone.0042956.t002
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The first analysis of Turkish ALS patients regarding ATXN2
confirms its role as a risk factor. More importantly, this study
identifies a common risk haplotype for ALS, containing the
ATXN2 and its neighbouring SH2B3 gene.
The initial observation that ataxin-2 acts as a modifier protein
of TDP-43 overexpression toxicity as a model of ALS risk was
consistent from Saccharomyces cerevisiae via Drosophila melanogaster to
Homo sapiens [14], and the role of ATXN2 intermediate expansions
as ALS risk factor was reproduced in every follow-up study
[15,16,17,18,19,20,21,22,34,41,42]. This effect is now also vali-
Figure 2. Haplotype block analysis of ATXN2 locus on chromosome 12q (110,300,000–110,550,000). Genotyped SNPs located in 250 kb
region were analyzed by Haploview 4.2 in order to identify haplotype blocks with ALS risk. A 136 kb large haplotype block, highlighted in red, was
observed in the analysis. The frequencies of haplotypes defined in this haplotype block, the p-values and permutation p-values are shown.
doi:10.1371/journal.pone.0042956.g002
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geographic distribution within Turkey or a particular phenotype
effect. The effect was limited to the expansion sizes 31 and 32 in
this study, while the association was not significant for interme-
diate expansion alleles of size ,30, and the very rare occurrence of
large expansion alleles in ALS was not detected, as would be
expected from the limited number of patients available. CAA
interruptions were detected in the expanded alleles of three out of
four ALS patients, but a pure CAG expansion was detected in one
ALS patient, suggesting that CAA interruptions are not a
prerequisite for ALS manifestation.
In our study, novel evidence indicates that ALS risk is impacted
by a 15-SNP haplotype block in linkage disequilibrium across the
genes ATXN2 and its downstream neighbour SH2B3. Haplotype
association became more significant when SNPs from both the
ATXN2 and SH2B3 genes were included; this suggests a role of
the SH2B3 gene in ALS risk. The SH2B3 protein, also known as
LNK, is a member of the SH2B (1–3) adaptor protein family.
They all contain Src Homology 2 (SH2) domains, pleckstrin motifs
and proline-rich regions. Thus, they can bind to phosphatidyli-
nositol-lipid containing membranes and to the phosphorylated
tyrosine residues, e.g. of receptor tyrosine kinases, modulating the
signal transduction that controls proliferation and growth. They
exert strong effects in hematopoiesis [43,44,45,46]. Preliminary
studies in the nervous system indicate that SH2B3, expressed in
cortical neurons from embryonic stages, competes with the other
family members (SH2B1 and SH2B2) and inhibits the NGF-
induced differentiation of PC12 cells reducing the neurite
outgrowth of cortical neurons, through binding of its SH2 domain
to the NGF receptor and repressing the PI3K pathway [47].
Previously, a SNP (rs3184504) in the SH2B3 gene was found
associated with multiple sclerosis [48]. ATXN2 has similar features
with SH2B3 since it contains proline-rich regions that interact
with Src Homology 3 domains, it associates with receptor tyrosine
kinases and modulates the signaling control of growth [23,27].
This first analysis of Turkish ALS patients on ATXN2, not only
confirmed its role as a risk factor in rare cases with intermediate
polyQ expansions, but also revealed novel evidence that SNPs
across the ATXN2/SH2B3 genomic locus may modulate risk in a
substantial fraction of ALS patients. These data need to be
validated in large and independent populations. In the light of
these findings, our results implicate a genetic (and a possible
biological) interaction between ATXN2 and SH2B3 genes,
therefore we propose that it will be useful to investigate genetic
variations in this genomic region of ALS patients.
Supporting Information
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